MCID: OVR012
MIFTS: 50

Ovarian Serous Cystadenocarcinoma malady

Cancer diseases category

Summaries for Ovarian Serous Cystadenocarcinoma

About this section


Disease Ontology:9 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary: Ovarian Serous Cystadenocarcinoma, also known as cystadenoma, serous, is related to cystadenocarcinoma and adenofibroma. An important gene associated with Ovarian Serous Cystadenocarcinoma is BIRC5 (baculoviral IAP repeat containing 5), and among its related pathways are TP53 network and Vinka Alkaloid Pathway, Pharmacokinetics. The compounds idoxifene and estradiol benzoate have been mentioned in the context of this disorder. Affiliated tissues include ovary and breast, and related mouse phenotypes are hearing/vestibular/ear and adipose tissue.

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
9Disease Ontology, 11DISEASES, 44Novoseek, 61UMLS, 39NCIt
See all sources

Ovarian Serous Cystadenocarcinoma, Aliases & Descriptions:

Name: Ovarian Serous Cystadenocarcinoma 9 11 44 61
Cystadenoma, Serous 61
 
Cystadenoma Serous 44
Serous Cystadenoma 9


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


External Ids:

Disease Ontology9 DOID:5746
NCIt39 C7978

Related Diseases for Ovarian Serous Cystadenocarcinoma

About this section

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 119)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma32.2MUC16
2adenofibroma31.0MUC16
3adenoma30.4BAX, BIRC5, ESR2, BCL2
4infertility30.2CYP19A1, ESR1, ESR2
5breast cancer29.8ESR2, CYP19A1, PGR, AKT1, ESR1
6endometriosis29.8MUC16, ESR1, CYP19A1, VEGFA, ESR2, PGR
7leukemia29.7BAX, BIRC5, ESR2, FAS, AKT1, BCL2
8ovarian cancer28.8BAX, PGR, BCL2, VEGFA, ESR2, FAS
9adenocarcinoma28.7AKT1, BCL2, BIRC5, BAX, FAS, MUC16
10cystadenoma11.2
11pancreatitis11.0
12pancreatic serous cystadenoma10.9
13serous cystadenocarcinoma10.9
14microcystic adenoma10.5
15pericardial effusion10.5MUC16
16cerebral meningioma10.4PGR
17pancreatic endocrine tumors10.4
18ovarian disease10.4MUC16, CYP19A1
19hypertension10.3
20sertoli-leydig cell tumor10.3
21obstructive jaundice10.3
22portal hypertension10.3
23endosalpingiosis10.3
24cystadenofibroma10.3
25leydig cell tumor10.3
26struma ovarii10.3
27tuberculosis10.3
28plasma cell leukemia10.3
29ovarian cyst10.3ESR2, MUC16, CYP19A1
30estrogen excess10.3CYP19A1, PGR
31malignant pleural mesothelioma10.2MUC16, BIRC5
32sertoli cell tumor10.2CYP19A1, PGR
33endocrine gland cancer10.2CYP19A1, ESR1
34ovarian hyperstimulation syndrome10.2CYP19A1, VEGFA
35benign meningioma10.2BIRC5, PGR
36progesterone resistance10.2PGR, ESR1
37uterine sarcoma10.2CYP19A1, ESR1
38cutaneous t cell lymphoma10.2BAX, FAS, BIRC5
39meningioma10.2PGR, ESR1
40cribriform carcinoma10.2PGR, ESR1
41hepatitis10.1
42islet cell tumor10.1
43pancreatic ductal adenocarcinoma10.1
44splenic artery aneurysm10.1
45von hippel-lindau disease10.1
46neuroendocrine carcinoma10.1
47fibroma10.1
48mucinous cystadenocarcinoma10.1
49compartment syndrome10.1
50conjunctivitis10.1

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to ovarian serous cystadenocarcinoma

Symptoms for Ovarian Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Ovarian Serous Cystadenocarcinoma

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

About this section

Anatomical Context for Ovarian Serous Cystadenocarcinoma

About this section

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

32
Ovary, Breast

Animal Models for Ovarian Serous Cystadenocarcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

36 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.2CYP19A1, ESR2, FAS, BCL2, BAX
2MP:00053759.0CYP19A1, ESR2, ESR1, AKT1, BCL2
3MP:00053718.9VEGFA, PGR, ESR2, ESR1, FAS, BAX
4MP:00053708.9CYP19A1, VEGFA, ESR2, ESR1, FAS, AKT1
5MP:00028738.8BIRC5, AKT1, ESR2, PGR, VEGFA, CYP19A1
6MP:00053888.6VEGFA, ESR2, ESR1, FAS, AKT1, BCL2
7MP:00020068.6VEGFA, PGR, ESR2, ESR1, FAS, AKT1
8MP:00053678.3USP2, VEGFA, ESR2, ESR1, FAS, BCL2
9MP:00053908.0CYP19A1, USP14, VEGFA, PGR, ESR2, ESR1
10MP:00053697.9CYP19A1, USP14, VEGFA, PGR, ESR2, ESR1
11MP:00053977.9CYP19A1, VEGFA, PGR, ESR2, ESR1, FAS
12MP:00053877.9ESR2, PGR, VEGFA, CYP19A1, ESR1, FAS
13MP:00107717.9CYP19A1, USP14, VEGFA, PGR, ESR2, ESR1
14MP:00053807.9VEGFA, PGR, NANOG, ESR1, AKT1, BIRC5
15MP:00036317.8CYP19A1, USP14, VEGFA, ESR2, ESR1, FAS
16MP:00030127.8USP2, VEGFA, PGR, NANOG, ESR2, ESR1
17MP:00053787.8CYP19A1, USP14, VEGFA, ESR2, ESR1, FAS
18MP:00053857.8CYP19A1, USP2, VEGFA, PGR, ESR2, ESR1
19MP:00053797.6CYP19A1, USP2, VEGFA, PGR, ESR2, ESR1
20MP:00053897.1BAX, CYP19A1, USP14, USP2, VEGFA, PGR
21MP:00053867.0CYP19A1, USP14, USP2, VEGFA, PGR, ESR2
22MP:00053766.8PGR, VEGFA, USP2, USP14, CYP19A1, ESR2
23MP:00107686.8USP14, VEGFA, PGR, NANOG, ESR2, ESR1
24MP:00053846.6NANOG, PGR, VEGFA, USP14, CYP19A1, ESR2

Publications for Ovarian Serous Cystadenocarcinoma

About this section

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 14)
idTitleAuthorsYear
1
Ovarian serous cystadenocarcinoma metastasising to the breast. (23445161)
2013
2
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. (21266826)
2010
3
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
4
Plasma cell leukemia with ovarian serous cystadenocarcinoma. (17883177)
2007
5
Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. (17553343)
2007
6
ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. (17160949)
2006
7
Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. (16793610)
2006
8
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
9
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
10
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. (10968352)
2000
11
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
12
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
13
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). (3165255)
1988
14
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. (3598277)
1987

Variations for Ovarian Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Expression patterns in normal tissues for genes affiliated with Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 58)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.9BAX, BCL2
29.9BAX, BCL2
39.8AKT1, BIRC5, BAX
4
Show member pathways
IL-9 Signaling Pathway37
Development Thrombopoietin regulated cell processes59
IL-7 Signaling Pathway37
Immune response IL 9 signaling pathway59
9.8AKT1, BIRC5, BAX
59.7ESR2, ESR1, AKT1
6
Show member pathways
Development Ligand independent activation of ESR1 and ESR259
9.7ESR2, ESR1, AKT1
79.7AKT1, ESR1, ESR2
89.7ESR2, PGR, CYP19A1
99.7BIRC5, BCL2, AKT1
10
Show member pathways
IL23-mediated signaling events37
Immune response IL 10 signaling pathway59
Angiopoietin receptor Tie2-mediated signaling37
Development PDGF signaling via STATs and NF kB59
Development Angiopoietin Tie2 signaling59
9.7AKT1, BCL2, BIRC5
11
Show member pathways
9.7ESR1, ESR2, CYP19A1
129.6BAX, BCL2, AKT1
139.6BAX, BCL2, AKT1
14
Show member pathways
Prostate Cancer37
Integrated Cancer pathway37
Steroid Biosynthesis37
9.6BAX, BCL2, AKT1
15
Show member pathways
Apoptosis and survival BAD phosphorylation59
Development Alpha 2 adrenergic receptor activation of ERK59
Chemotaxis CXCR4 signaling pathway59
9.6BAX, BCL2, AKT1
16
Show member pathways
9.6AKT1, BCL2, BAX
17
Show member pathways
9.6AKT1, BCL2, BAX
18
Show member pathways
9.6AKT1, BCL2, BAX
199.6AKT1, BCL2, BAX
20
Show member pathways
Nuclear Receptors37
9.6PGR, ESR2, ESR1
21
Show member pathways
Cell cycle ESR1 regulation of G1 S transition59
Immune response MIF JAB1 signaling59
Cell cycle Cell cycle generic schema 59
9.6AKT1, ESR1, PGR
229.6BAX, BCL2, FAS
23
Show member pathways
9.6FAS, BCL2, BAX
249.6BCL2, AKT1, ESR1
25
Show member pathways
Development VEGF signaling via VEGFR2 generic cascades59
9.5VEGFA, ESR1, AKT1
269.5VEGFA, AKT1, BCL2
279.4AKT1, BCL2, BIRC5, BAX
28
Show member pathways
Signal transduction PTEN pathway59
9.4BAX, BIRC5, BCL2, AKT1
29
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways59
9.4BAX, BIRC5, BCL2, FAS
309.4FAS, BCL2, BIRC5, BAX
31
Show member pathways
Apoptosis and survival TNFR1 signaling pathway59
TWEAK Signaling Pathway37
Apoptosis Modulation by HSP7037
HIV-1 Nef- Negative effector of Fas and TNF-alpha37
9.4FAS, AKT1, BCL2, BAX
32
Show member pathways
9.4FAS, AKT1, BCL2, BAX
33
Show member pathways
9.4FAS, AKT1, BCL2, BAX
34
Show member pathways
FAS pathway and Stress induction of HSP regulation37
Apoptosis and survival FAS signaling cascades59
Caspase cascade in apoptosis37
9.4FAS, AKT1, BCL2, BAX
359.3ESR2, ESR1, BCL2, BAX
36
Show member pathways
Cytoskeleton remodeling FAK signaling59
Development Endothelin 1 EDNRA transactivation of EGFR59
9.3AKT1, ESR1, ESR2, VEGFA
37
Show member pathways
Apoptosis Modulation and Signaling37
Apoptosis37
9.1FAS, AKT1, BCL2, BIRC5, BAX
38
Show member pathways
Toll-like receptor signaling pathway37
Regulation of toll-like receptor signaling pathway37
9.1FAS, AKT1, BCL2, BIRC5, BAX
39
Show member pathways
9.1BAX, BIRC5, BCL2, AKT1, FAS
40
Show member pathways
9.1ESR2, ESR1, AKT1, BCL2, BIRC5
41
Show member pathways
Prolactin Signaling Pathway37
Development Prolactin receptor signaling59
Leptin signaling pathway37
9.1ESR2, ESR1, AKT1, BCL2, BAX
429.0VEGFA, NANOG, ESR2
43
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor37
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
9.0ESR1, FAS, AKT1, BCL2, BAX
44
Show member pathways
9.0BAX, BCL2, AKT1, FAS, VEGFA
45
Show member pathways
8.9NANOG, ESR2, ESR1, AKT1
46
Show member pathways
DNA damage response (only ATM dependent)37
Wnt Signaling Pathway and Pluripotency37
8.8BAX, BCL2, AKT1, NANOG
478.8VEGFA, FAS, AKT1, BCL2, BIRC5, BAX
488.7CYP19A1, VEGFA, ESR1, AKT1, BCL2, BAX
498.4VEGFA, NANOG, ESR1, FAS, AKT1
508.4BAX, VEGFA, ESR2, ESR1, FAS, AKT1

Compounds for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Compounds related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 235)
idCompoundScoreTop Affiliating Genes
1idoxifene449.7PGR, ESR1, CYP19A1
2estradiol benzoate449.7ESR1, PGR, CYP19A1, ESR2
3nandrolone44 2510.7CYP19A1, PGR, ESR1, ESR2
4leuprolide acetate449.7ESR1, ESR2, PGR, CYP19A1
5anastrozole44 50 1211.6ESR1, PGR, CYP19A1, ESR2
6exemestane44 50 60 1212.6ESR1, CYP19A1, PGR, ESR2
7bisphenol a449.6PGR, CYP19A1, ESR2, ESR1
8lapatinib44 50 1211.6BIRC5, PGR, CYP19A1, ESR1
9clomiphene citrate449.6ESR2, ESR1, PGR, CYP19A1
103,3-diindolylmethane449.6BAX, BIRC5, ESR1, VEGFA
11hoechst 33342449.6BCL2, BIRC5, FAS, BAX
12toremifene44 1210.5CYP19A1, PGR, ESR1, FAS, ESR2
13fulvestrant44 50 29 1212.5ESR1, CYP19A1, PGR, ESR2
144-hydroxytamoxifen449.4CYP19A1, PGR, ESR2, ESR1, AKT1
15letrozole44 50 60 1212.4ESR1, ESR2, PGR, CYP19A1
16indole-3-carbinol449.3CYP19A1, ESR1, AKT1, BIRC5, BCL2, BAX
17gefitinib44 50 1211.2BIRC5, AKT1, ESR1, ESR2, VEGFA, CYP19A1
18adriamycin449.2PGR, FAS, AKT1, BAX, BCL2, BIRC5
19celecoxib44 60 29 50 25 1214.2BCL2, AKT1, VEGFA, CYP19A1, BIRC5, BAX
20progestin449.2PGR, VEGFA, ESR2, ESR1, CYP19A1
21gemcitabine44 50 1211.2BAX, BCL2, AKT1, VEGFA, CYP19A1, BIRC5
22thymidylate449.1FAS, ESR2, BIRC5, BAX, VEGFA, BCL2
23trastuzumab44 50 1211.1CYP19A1, VEGFA, PGR, ESR1, FAS, BIRC5
24egcg449.1BAX, VEGFA, ESR2, FAS, BCL2, BIRC5
25taxane449.1ESR1, BCL2, PGR, CYP19A1, VEGFA, BIRC5
26levonorgestrel44 60 29 1212.1ESR1, PGR, CYP19A1, ESR2
27etoposide44 50 60 1212.0BAX, BIRC5, BCL2, FAS, ESR2, AKT1
28mifepristone44 29 60 1211.9CYP19A1, VEGFA, PGR, ESR2, ESR1, BAX
29arsenite44 259.9AKT1, VEGFA, FAS, PGR, BAX, BIRC5
30mg 13244 609.9BIRC5, BCL2, BAX, VEGFA, AKT1, FAS
31docetaxel44 50 60 1211.8CYP19A1, BAX, PGR, BIRC5, BCL2, ESR1
32ly294002448.8ESR1, FAS, AKT1, VEGFA, BCL2, BIRC5
33sb 20358044 609.8BAX, BCL2, AKT1, FAS, VEGFA, BIRC5
34cyclophosphamide44 50 1210.7BCL2, MUC16, ESR1, PGR, VEGFA, CYP19A1
35n acetylcysteine448.7FAS, VEGFA, AKT1, BAX, BCL2, BIRC5
36actinomycin d448.6BCL2, BIRC5, BAX, ESR1, VEGFA, ESR2
37resveratrol44 60 25 1211.6VEGFA, PGR, ESR2, ESR1, FAS, BCL2
385fluorouracil448.5BCL2, BAX, BIRC5, CYP19A1, ESR1, FAS
39testosterone44 60 25 1211.5FAS, MUC16, AKT1, BIRC5, ESR1, ESR2
40cisplatin44 50 60 1211.4MUC16, FAS, AKT1, BCL2, ESR1, BIRC5
41retinoic acid44 259.4BIRC5, BAX, BCL2, AKT1, FAS, ESR2
42dexamethasone44 50 29 1211.1ESR2, VEGFA, CYP19A1, PGR, FAS, AKT1
43genistein44 29 60 3 25 1213.1AKT1, FAS, ESR1, ESR2, PGR, VEGFA
44tamoxifen44 50 29 1211.1PGR, VEGFA, CYP19A1, ESR2, ESR1, BAX
45cycloheximide448.1BIRC5, BAX, AKT1, BCL2, PGR, FAS
46paraffin447.9BAX, BIRC5, BCL2, AKT1, FAS, MUC16
47vegf447.9VEGFA, AKT1, PGR, BCL2, MUC16, ESR1
48estrogen447.9VEGFA, CYP19A1, MUC16, ESR2, PGR, ESR1
49paclitaxel44 50 129.9MUC16, BAX, BIRC5, BCL2, AKT1, FAS
50doxorubicin44 50 129.6CYP19A1, BAX, ESR2, BIRC5, BCL2, FAS

GO Terms for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:0469309.8BAX, BCL2
2mitochondrial outer membraneGO:0057419.3PGR, BCL2, BAX
3nucleoplasmGO:0056548.2ZNF217, AKT1, ESR1, ESR2, NANOG, PGR
4nucleusGO:0056347.1NANOG, ESR2, ESR1, FAS, AKT1, BCL2

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 43)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:00692410.4AKT1, FAS
2transformed cell apoptotic processGO:00692710.3FAS, BAX
3regulation of nitrogen utilizationGO:00680810.3BAX, BCL2
4uterus developmentGO:06006510.3ESR2, ESR1
5regulation of protein heterodimerization activityGO:04349710.3BCL2, BAX
6positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:200124110.3BAX, FAS
7regulation of protein homodimerization activityGO:04349610.3BCL2, BAX
8endoplasmic reticulum calcium ion homeostasisGO:03246910.3BCL2, BAX
9positive regulation of nitric-oxide synthase activityGO:05100010.3ESR1, AKT1
10response to acidGO:00110110.2BAX, BCL2
11renal system processGO:00301410.2FAS, BCL2
12negative regulation of autophagyGO:01050710.2AKT1, BCL2
13negative regulation of apoptotic signaling pathwayGO:200123410.2BCL2, BAX
14androgen metabolic processGO:00820910.2CYP19A1, ESR1
15cellular response to organic substanceGO:07131010.2BCL2, BAX
16intracellular estrogen receptor signaling pathwayGO:03052010.2ESR1, ESR2
17apoptotic mitochondrial changesGO:00863710.2BAX, AKT1
18B cell homeostasisGO:00178210.1BCL2, BAX
19positive regulation of blood vessel endothelial cell migrationGO:04353610.1VEGFA, AKT1
20mammary gland alveolus developmentGO:06074910.1VEGFA, ESR1
21vagina developmentGO:06006810.1ESR2, ESR1, BAX
22regulation of mitochondrial membrane potentialGO:05188110.1BAX, BCL2
23intrinsic apoptotic signaling pathwayGO:09719310.0AKT1, BCL2, BAX
24negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:04315410.0BIRC5, AKT1, VEGFA
25positive regulation of sequence-specific DNA binding transcription factor activityGO:05109110.0AKT1, ESR1, ESR2
26homeostasis of number of cells within a tissueGO:04887310.0BAX, BCL2
27extrinsic apoptotic signaling pathway via death domain receptorsGO:00862510.0FAS, BCL2, BAX
28extrinsic apoptotic signaling pathway in absence of ligandGO:09719210.0BAX, BCL2, FAS
29intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressGO:07005910.0BCL2, BAX
30response to toxic substanceGO:00963610.0BAX, BCL2, FAS
31release of cytochrome c from mitochondriaGO:0018369.9BAX, BCL2
32positive regulation of peptidyl-serine phosphorylationGO:0331389.9BCL2, AKT1, VEGFA
33cellular response to hypoxiaGO:0714569.9BCL2, AKT1, VEGFA
34response to gamma radiationGO:0103329.9BAX, BCL2
35ovarian follicle developmentGO:0015419.7BAX, BCL2, ESR2, VEGFA
36transcription initiation from RNA polymerase II promoterGO:0063679.6ESR1, ESR2, PGR
37positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:19007409.6BCL2, AKT1
38apoptotic processGO:0069159.5FAS, AKT1, BCL2, BIRC5, BAX
39negative regulation of apoptotic processGO:0430669.4VEGFA, FAS, AKT1, BCL2, BIRC5
40signal transductionGO:0071659.4PGR, ESR2, ESR1, FAS, AKT1
41positive regulation of mitotic cell cycleGO:0459319.2BIRC5, NANOG, USP2
42ubiquitin-dependent protein catabolic processGO:0065119.0USP14, USP2, UBE4A
43negative regulation of transcription from RNA polymerase II promoterGO:0001228.3USP2, VEGFA, NANOG, ESR2

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:03405610.1ESR1, ESR2
2estrogen receptor activityGO:03028410.0ESR2, ESR1
3BH3 domain bindingGO:05143410.0BAX, BCL2
4core promoter sequence-specific DNA bindingGO:0010469.9ESR1, ESR2
5nitric-oxide synthase regulator activityGO:0302359.9AKT1, ESR1
6steroid bindingGO:0054969.8ESR1, ESR2, PGR
7steroid hormone receptor activityGO:0037079.8PGR, ESR2, ESR1
8channel activityGO:0152679.8BAX, BCL2
9enzyme bindingGO:0198999.4PGR, ESR2, ESR1, AKT1, BIRC5
10protein heterodimerization activityGO:0469829.0VEGFA, BCL2, BIRC5, BAX
11identical protein bindingGO:0428028.1BAX, USP2, VEGFA, ESR1, FAS, AKT1
12protein bindingGO:0055155.6ESR1, ESR2, PGR, VEGFA, USP2, USP14

Products for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Ovarian Serous Cystadenocarcinoma

About this section
4CDC
14ExPASy
15FMA
23GTR
24HGMD
25HMDB
26ICD10
27ICD10 via Orphanet
28ICD9CM
29IUPHAR
30KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet